bpc 157 human clinical trial gastrointestinal Peptide BPC-157 Stable gastric pentadecapeptide BPC 157

References Vasireddi N, Hahamyan H, Salata MJ, et al

Its published study focuses on the safety data - and not the efficacy data - which basically showed that those on the drug were lucky to lose 1 kilogram after 24 weeks

The primary concern raised by the Norwegian IRB was that this RCT was violating the principle of clinical equipoise

These reactions typically resolve with continued use as the skin acclimates, or with dose reduction

Also, it is important to point out that "average" levels of the neurotypical group may not necessarily be optimal, as they were on typical western diets that are probably not nutritionally optimal